Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
132.21
-0.10 (-0.08%)
Oct 9, 2025, 11:39 AM EDT - Market open
Novartis AG Revenue
Novartis AG had revenue of $14.84B in the quarter ending June 30, 2025, with 15.26% growth. This brings the company's revenue in the last twelve months to $55.19B, up 12.95% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$55.19B
Revenue Growth
+12.95%
P/S Ratio
4.66
Revenue / Employee
$727,251
Employees
75,883
Market Cap
257.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
NVS News
- 2 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 6 days ago - Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance - Seeking Alpha
- 8 days ago - Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - PRNewsWire
- 8 days ago - US FDA approves Novartis' drug for skin disease - Reuters
- 10 days ago - Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S. - WSJ
- 10 days ago - Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US - GlobeNewsWire
- 10 days ago - Novartis announces commencement of tender offer to acquire Tourmaline Bio - GlobeNewsWire
- 13 days ago - Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025 - GlobeNewsWire